Literature DB >> 8960845

Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up.

M Hanefeld1, S Fischer, U Julius, J Schulze, U Schwanebeck, H Schmechel, H J Ziegelasch, J Lindner.   

Abstract

The Diabetes Intervention Study (DIS) is a prospective population-based multicentre trial of newly detected cases of non-insulin-dependent diabetes mellitus (NIDDM). This report analyses the risk factors for subsequent coronary heart disease and all-cause death during the 11-year follow-up. The prognostic significance of the categories of the NIDDM Policy Group was validated with respect to the incidence of coronary heart disease and mortality. At baseline 1139 subjects, aged 30-55 years at the time of diabetes detection and classified as diet controlled after a 6-week screening phase, were included. Of the patients 112 (15.2%) suffered from myocardial infarction, 197 (19.82%) of 994 had died. The odds ratio for all-cause mortality compared to the general population for males at the age of 36-45 years was 5.1 and for females 7.0. In multivariate analysis age, blood pressure and smoking were independent risk factors for myocardial infarction and male sex, age, blood pressure, triglycerides, postprandial blood glucose and smoking for death, respectively. The categories of the NIDDM Policy Group target parameters for blood glucose, triglycerides and blood pressure were significant predictors of both CHD and death. Thus, it appears that in NIDDM good control of blood glucose, blood pressure and triglycerides is associated with a lower incidence of coronary heart disease and death rate respectively.

Entities:  

Mesh:

Year:  1996        PMID: 8960845     DOI: 10.1007/s001250050617

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  158 in total

1.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.

Authors:  I M Stratton; A I Adler; H A Neil; D R Matthews; S E Manley; C A Cull; D Hadden; R C Turner; R R Holman
Journal:  BMJ       Date:  2000-08-12

2.  Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.

Authors:  A I Adler; I M Stratton; H A Neil; J S Yudkin; D R Matthews; C A Cull; A D Wright; R C Turner; R R Holman
Journal:  BMJ       Date:  2000-08-12

3.  Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin.

Authors:  T Nakagami
Journal:  Diabetologia       Date:  2004-02-18       Impact factor: 10.122

4.  Prediction of the risk to develop diabetes-related late complications by means of the glucose pentagon model: analysis of data from the Juvenile Diabetes Research Foundation continuous glucose monitoring study.

Authors:  Andreas Thomas; Lutz Heinemann
Journal:  J Diabetes Sci Technol       Date:  2012-05-01

Review 5.  Impact of postprandial glycaemia on health and prevention of disease.

Authors:  E E Blaak; J-M Antoine; D Benton; I Björck; L Bozzetto; F Brouns; M Diamant; L Dye; T Hulshof; J J Holst; D J Lamport; M Laville; C L Lawton; A Meheust; A Nilson; S Normand; A A Rivellese; S Theis; S S Torekov; S Vinoy
Journal:  Obes Rev       Date:  2012-07-11       Impact factor: 9.213

Review 6.  Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy.

Authors:  L Monnier; C Colette; S Dejager; D R Owens
Journal:  Rev Endocr Metab Disord       Date:  2016-03       Impact factor: 6.514

Review 7.  Prandial glucose regulation in the glucose triad: emerging evidence and insights.

Authors:  Paul Beisswenger; Robert J Heine; Lawrence A Leiter; Alan Moses; Jaakko Tuomilehto
Journal:  Endocrine       Date:  2004-12       Impact factor: 3.633

8.  Pramlintide reduces the risks associated with glucose variability in type 1 diabetes.

Authors:  Boris P Kovatchev; John Crean; Anthony McCall
Journal:  Diabetes Technol Ther       Date:  2008-10       Impact factor: 6.118

9.  Open-label, randomized, multiple-center, parallel study comparing glycemic responses and safety profiles of Glucerna versus Fresubin in subjects of type 2 diabetes mellitus.

Authors:  Wei-Qing Wang; Yi-Fei Zhang; Da-Jin Zhou; Zhi-Min Liu; Xu Hong; Ming-Cai Qiu; Yong-Quan Shi; Pei-Jin Xia; Jin Lu; Mao-Jing Xu; Liang An; Wei Feng; Peng Zhang; J Schwamman; Guang Ning
Journal:  Endocrine       Date:  2008-04-10       Impact factor: 3.633

Review 10.  Premixed insulin analogues for the treatment of diabetes mellitus.

Authors:  Alan J Garber
Journal:  Drugs       Date:  2006       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.